Literature DB >> 21097900

Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.

Gallen B Triana-Baltzer1, Rebecca L Sanders, Maria Hedlund, Kellie A Jensen, Laura M Aschenbrenner, Jeffrey L Larson, Fang Fang.   

Abstract

BACKGROUND: influenza viruses (IFVs) frequently achieve resistance to antiviral drugs, necessitating the development of compounds with novel mechanisms of action. DAS181 (Fludase), a sialidase fusion protein, may have a reduced potential for generating drug resistance due to its novel host-targeting mechanism of action.
METHODS: IFV strains B/Maryland/1/59 and A/Victoria/3/75 (H3N2) were subjected to >30 passages under increasing selective pressure with DAS181. The DAS181-selected IFV isolates were characterized in vitro and in mice.
RESULTS: despite extensive passaging, DAS181-selected viruses exhibited a very low level of resistance to DAS181, which ranged between 3- and 18-fold increase in EC(50). DAS181-selected viruses displayed an attenuated phenotype in vitro, as exhibited by slower growth, smaller plaque size and increased particle to pfu ratios relative to wild-type virus. Further, the DAS181 resistance phenotype was unstable and was substantially reversed over time upon DAS181 withdrawal. In mice, the DAS181-selected viruses exhibited no greater virulence than their wild-type counterparts. Genotypic and phenotypic analysis of DAS181-selected viruses revealed mutations in the haemagglutinin (HA) and neuraminidase (NA) molecules and also changes in HA and NA function.
CONCLUSIONS: results indicate that resistance to DAS181 is minimal and unstable. The DAS181-selected IFV isolates exhibit reduced fitness in vitro, likely due to altered HA and NA functions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21097900      PMCID: PMC3001847          DOI: 10.1093/jac/dkq387

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  60 in total

1.  Swine flu outbreak. What role for antiviral drugs?

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2009-05-08       Impact factor: 47.728

2.  DAS181 inhibits H5N1 influenza virus infection of human lung tissues.

Authors:  Renee W Y Chan; Michael C W Chan; Adam C N Wong; Rositsa Karamanska; Anne Dell; Stuart M Haslam; Alan D L Sihoe; W H Chui; Gallen Triana-Baltzer; Qixiang Li; J S Malik Peiris; Fang Fang; John M Nicholls
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

3.  A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding.

Authors:  Ellen Z Baum; Pamela C Wagaman; Linh Ly; Ignatius Turchi; Jianhua Le; Doris Bucher; Karen Bush
Journal:  Antiviral Res       Date:  2003-06       Impact factor: 5.970

4.  DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis.

Authors:  Gallen B Triana-Baltzer; Maria Babizki; Michael C W Chan; Adam C N Wong; Laura M Aschenbrenner; Erin R Campbell; Qi-Xiang Li; Renee W Y Chan; J S Malik Peiris; John M Nicholls; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2009-11-26       Impact factor: 5.790

5.  Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin.

Authors:  Aarthi Chandrasekaran; Aravind Srinivasan; Rahul Raman; Karthik Viswanathan; S Raguram; Terrence M Tumpey; V Sasisekharan; Ram Sasisekharan
Journal:  Nat Biotechnol       Date:  2008-01-06       Impact factor: 54.908

Review 6.  The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus.

Authors:  Nikole M Scalera; Sherif B Mossad
Journal:  Postgrad Med       Date:  2009-09       Impact factor: 3.840

7.  Structural basis for receptor specificity of influenza B virus hemagglutinin.

Authors:  Qinghua Wang; Xia Tian; Xiaorui Chen; Jianpeng Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

8.  Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility.

Authors:  Jessica A Belser; Ola Blixt; Li-Mei Chen; Claudia Pappas; Taronna R Maines; Neal Van Hoeven; Ruben Donis; Julia Busch; Ryan McBride; James C Paulson; Jacqueline M Katz; Terrence M Tumpey
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-27       Impact factor: 11.205

9.  Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

Authors:  J McKimm-Breschkin; T Trivedi; A Hampson; A Hay; A Klimov; M Tashiro; F Hayden; M Zambon
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.

Authors:  Gallen B Triana-Baltzer; Larisa V Gubareva; John M Nicholls; Melissa B Pearce; Vasiliy P Mishin; Jessica A Belser; Li-Mei Chen; Renee W Y Chan; Michael C W Chan; Maria Hedlund; Jeffrey L Larson; Ronald B Moss; Jacqueline M Katz; Terrence M Tumpey; Fang Fang
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

View more
  22 in total

Review 1.  Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.

Authors:  Roy F Chemaly; Dimpy P Shah; Michael J Boeckh
Journal:  Clin Infect Dis       Date:  2014-11-15       Impact factor: 9.079

Review 2.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

3.  Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.

Authors:  Chunlong Ma; Jiantao Zhang; Jun Wang
Journal:  Mol Pharmacol       Date:  2016-07-06       Impact factor: 4.436

4.  Management of respiratory viral infections in hematopoietic cell transplant recipients.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Victor E Mulanovich; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Am J Blood Res       Date:  2012-11-25

Review 5.  Antiviral strategies against influenza virus: towards new therapeutic approaches.

Authors:  Arianna Loregian; Beatrice Mercorelli; Giulio Nannetti; Chiara Compagnin; Giorgio Palù
Journal:  Cell Mol Life Sci       Date:  2014-04-04       Impact factor: 9.261

6.  Current management of parainfluenza pneumonitis in immunocompromised patients: a review.

Authors:  Ann R Falsey
Journal:  Infect Drug Resist       Date:  2012-08-08       Impact factor: 4.003

7.  Experimental evolution of an RNA virus in cells with innate immunity defects.

Authors:  Pablo Hernández-Alonso; Raquel Garijo; José M Cuevas; Rafael Sanjuán
Journal:  Virus Evol       Date:  2015-09-03

Review 8.  Influenza antivirals currently in late-phase clinical trial.

Authors:  Paulina Koszalka; Danielle Tilmanis; Aeron C Hurt
Journal:  Influenza Other Respir Viruses       Date:  2017-02-28       Impact factor: 4.380

9.  Modular glycosphere assays for high-throughput functional characterization of influenza viruses.

Authors:  Sven N Hobbie; Karthik Viswanathan; Ido Bachelet; Udayanath Aich; Zachary Shriver; Vidya Subramanian; Rahul Raman; Ram Sasisekharan
Journal:  BMC Biotechnol       Date:  2013-04-15       Impact factor: 2.563

10.  Networks of Host Factors that Interact with NS1 Protein of Influenza A Virus.

Authors:  Sathya N Thulasi Raman; Yan Zhou
Journal:  Front Microbiol       Date:  2016-05-04       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.